



E  
U  
R  
O  
P  
E  
A  
N  
  
T  
H  
Y  
R  
O  
I  
D  
  
A  
S  
S  
O  
C  
I  
A  
T  
I  
O  
N  
  
C  
A  
N  
C  
E  
R  
  
R  
E  
S  
E  
A  
R  
C  
H  
  
N  
E  
T  
W  
O  
R  
K

# 9th ETA-CRN Meeting

5th September, 2009

Lisbon, Portugal

<b>President:</b>	<b>Ulla Feldt-Rasmussen, National University Hospital, Copenhagen, DK</b>
<b>Secretary:</b>	<b>Barbara Jarzab, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland</b>
<b>Treasurer:</b>	<b>Georg Brabant, The University of Manchester, UK</b>

*9<sup>th</sup> ETA-CRN Meeting*  
*Lisbon, Portugal*  
*September 5<sup>th</sup>, 2009*  
**9.00 – 15.30**

**MEDULLARY THYROID CANCER MANAGEMENT GUIDELINES  
OF THE AMERICAN THYROID ASSOCIATION: EUROPEAN COMMENTS**

PROGRAMME

8.20 – 8.50 Registration and coffee

8.50 – 9.00 Welcome and Opening

President ETA-CRN, Ulla Feldt-Rasmussen  
Secretary ETA-CRN Barbara Jarzab

Chairmen: Ulla Feldt-Rasmussen, Barbara Jarzab, Martin Schlumberger

9.00 – 9.45

**Presentation of Medullary Thyroid Cancer Management Guidelines of the American Thyroid Association**

Richard T. Kloos (Columbus, Ohio)

9.45 – 14.45

**Discussion on European comments to ATA MTC management guidelines**

(each speaker presents his stand and comments to the respective ATA guidelines in 10 minutes and the next 5 minutes are for discussion)

Part 1:

**Issues related to diagnosis, treatment and monitoring of clinically detectable MTC**

- 1 9.45 – 10.00 **Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC.**  
Rosella Elisei (Pisa, Italy)
  - 2 10.00 – 10.15 **Serum calcitonin estimation in medullary thyroid cancer patients: basal or stimulated levels?**  
Chantal Daumerie (Brussels, Belgium)
  - 3 10.15 – 10.30 **Preoperative evaluation and staging of MTC diagnosed / supposed by FNA or serum CT – role of imaging modalities (CT/MR/PET) and serum CT level.**  
Bruno Niederle (Vienna, Austria)
- 10.30 – 10.45 **Coffee break**

- 4 10.45 – 11.00 **Extent of surgery in clinically evident but operable MTC – when is central and/or lateral lymphadenectomy indicated**  
Sophie Leboulleux (Paris, France)
- 5 11.00 – 11.15 **Postoperative follow up in patients showing no evident residual disease - cut-offs for imaging/ intervention**  
Michele Minuto (Pisa, Italy)
- 6 11.15 – 11.30 **Treatment of advanced medullary thyroid cancer**  
Lars Bastholt (Odense, Denmark)
- 7 11.30-11.45 **Functional PET imaging and Peptide Receptor Radioisotope Therapy in MTC**  
Marcus Luster (Ulm, Germany)
- 8 11.45-12.00 **Clinical comments related to MTC diagnosis and management**  
Leonidas Duntas (Athens, Greece)
- 9 12.00-12.15 **General discussion**
- 12.15-13.00 **LUNCH BREAK**

Part 2:~

**Issues related to early diagnosis and management of hereditary MTC and MEN2**

- 10 13.00 – 13.15 **What is the optimal range of RET mutations to be tested?**  
Laura Fugazzola (Milan, Italy)
- 11 13.15 – 13.30 **Genotype – phenotype correlations in RET mutation carriers and the ATA risk-based classification of RET mutations**  
Friedhelm Raue (Heidelberg, Germany)
- 12 13.30 – 13.45 **Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers – the role of calcitonin serum level**  
Barbara Jarzab (Gliwice, Poland)
- 13 13.45 – 14.00 **Extent and timing of thyroidectomy in RET mutation carriers**  
Bruno Niederle (Vienna, Austria)
- 14 14.00 – 14.15 **Hyperparathyroidism in MEN2A**  
Maria Alevizaki (Athens, Greece)
- 15 14.15 – 14.30 **Diagnosis and treatment of pheochromocytoma in MEN2A**  
Hartmut Neumann (Freiburg, Germany)
- 16 14.30 – 14.50 **ATA MTC guidelines and their comparison with the European practice: pro and contra**  
Furio Pacini (Siena, Italy) and Francois Borson-Chazot (Lyon, France)
- 17 14.50-15.30 **General comments, discussion and time lines for final manuscript**

\*\*\*\*\*